Navigation Links
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Date:7/23/2009

SOUTH SAN FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that in the TASKi3 Phase 2b clinical trial in rheumatoid arthritis (RA) patients who had failed to respond to at least one biologic treatment, the group treated with R788 (fostamatinib disodium) did not report significantly higher ACR 20, ACR 50, ACR 70 and DAS28 response rates than the placebo group at three months, and therefore, the trial failed to meet its efficacy endpoints. The objective components (CRP and ESR)* of these ACR scores did show a statistically significant difference; however, the subjective reported response rate components did not as compared to placebo. Although the ACR scores for the R788 group were within the expected range in this patient population, the reported placebo response rates were considerably higher than seen in any other previous study of RA biologic failure patients and rose unaccountably between week 6 (at which point the reported response rates between R788 and placebo were significantly different) and month 3 (when such reported response rates were no longer significantly different).

TASKi3 was the first clinical trial evaluating R788 in which anatomical changes in the patients' wrist and hands were evaluated using Magnetic Resonance Imaging (MRI) and scored using the RAMRIS (Rheumatoid Arthritis Magnetic Resonance Imaging Scoring) system. Those results showed improvements in the treated group versus the placebo group in the Synovitis and Osteitis scores, while the Erosion scores, known to be the slowest to change, showed no significant effect at three months. The most frequent adverse events were as expected from the earlier TASKi trials and appear to be manageable.

Rigel will host a conference call today at 7PM EDT/ 4PM PDT
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 24, 2013 3SBio ... the "Company"), a leading China ... and marketing biopharmaceutical products, announced today that, at ... the Company,s shareholders voted in favor of the ... agreement and plan of merger dated February 8, ...
(Date:5/23/2013)... PARÍS, 24 de mayo de 2013  Volcano ... desarrollador y fabricante de herramientas de precisión para ... tratamiento de la enfermedad vascular periférica y coronaria, ... ( Ad enosine V asodilator I ... durante la sesión de ensayo clínico hot line ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... PALO ALTO, Calif., Feb. 9, 2011 Telik, Inc. (Nasdaq: ... Wick, M.D., Ph.D. will provide a corporate overview at the ... City on Tuesday, February 15 at 3:00 p.m. Eastern time ... A live and archived webcast of the presentation will be ...
... MATEO, Calif., Feb. 8, 2011 NeurogesX, Inc. (Nasdaq: ... developing and commercializing novel pain management therapies, announced today ... scheduled to present at two upcoming conferences in New ... Investor Conference, to be held February 14-15, 2011 at ...
Cached Medicine Technology:NeurogesX to Present at Two February Investor Conferences 2NeurogesX to Present at Two February Investor Conferences 3
(Date:5/24/2013)... 2013 This week is National EMS ... efforts to provide the best emergency care and to ... week is also to educate the public that all ... Citizens are the first link, and a very important ... CPR after a cardiac arrest can triple a victim’s ...
(Date:5/24/2013)... Pomona, Calif. (PRWEB) May 24, 2013 ... has retained its status of “Full Accreditation” for the ... (AVMA) Council on Education (COE). , “This is a ... of our hard work and student outcomes,” said College ... want to express my appreciation to the faculty, staff, ...
(Date:5/24/2013)... The Mirena IUD lawyers at ... the FDA has received more than 59,229 complaints since 2004 ... intrauterine birth control device known as the Mirena IUD.* , ... by the women “included ‘expulsion,’ where the IUD came out ... according to an ABC News article. “Abdominal pain is also ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Gift ... Cards, major competitors in sustainable card material, are ... using forest materials as a sustainable gift card ... to identify industry challenges and increase education and ... programs to support the reduction of carbon footprint ...
(Date:5/24/2013)... failed to replicate what appeared to be breakthrough results ... were published last year in the journal Science ... suggested that the drug bexarotene (marketed as Targretin) could ... a pathological hallmark of Alzheimer,s disease in ... the 2012 report, drug treatment quickly removed most of ...
Breaking Medicine News(10 mins):Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3
... SAN FRANCISCO, March 24 Epiphany Biosciences announced ... IND with the Food and Drug Administration (FDA) ... antiviral medication valomaciclovir (EPB-348) as an adjunctive therapy ... shown to possess potent antiviral activity in vitro ...
... Reverse Split Ratio of Outstanding Cellegy Common Stock Expected ... Cellegy Pharmaceuticals, Inc. (OTC Bulletin Board: CLGY) today announced ... Corporation approved the previously announced merger of the two ... The transaction, which is subject to customary closing ...
... and average selling prices to be affected into ... 24 According to Millennium Research Group,s (MRG,s) ... includes arthroplasty implants (shoulder, elbow, digit, ankle, and ... the double-digit market growth seen in recent years ...
... Calif., March 24 According to a new Harris ... being able to afford medical care and prescription medications.(1) ... children and working-age Americans went without needed prescription medications in ... in 2003. Experts predict these statistics are likely to ...
... Wuesthoff saves 16 percent system-wide on orthopedic spend , ... ... Wuesthoff Health System has renewed its supply chain relationship with Broadlane. ... of consumable supplies, equipment, pharmaceuticals and purchased services to help manage ...
... Regal International, Inc., doing business as Beauty ... by EMK Products, LLC to be the exclusive ... line. Under the agreement, Beauty Beverly Hills will ... and management of internet affiliates, marketing and sales.Beauty ...
Cached Medicine News:Health News:Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS) 2Health News:Cellegy and Adamis Stockholders Approve Merger Transaction and Related Proposals 2Health News:Cellegy and Adamis Stockholders Approve Merger Transaction and Related Proposals 3Health News:Job Loss Means Fewer Americans Have Health Care Coverage: How Will the Economic Downturn Affect the Small-Joint Implant Market? 2Health News:*** Diabetes Alert Day *** OneTouch(R) Offers Cost Saving Tips to Help Diabetes Patients Maintain Good Health in Tough Economy 2Health News:*** Diabetes Alert Day *** OneTouch(R) Offers Cost Saving Tips to Help Diabetes Patients Maintain Good Health in Tough Economy 3Health News:*** Diabetes Alert Day *** OneTouch(R) Offers Cost Saving Tips to Help Diabetes Patients Maintain Good Health in Tough Economy 4Health News:Wuesthoff Health System and Broadlane Continue Exclusive Relationship; Orthopedic Consulting Initiative Yields Significant Savings 2Health News:Wuesthoff Health System and Broadlane Continue Exclusive Relationship; Orthopedic Consulting Initiative Yields Significant Savings 3Health News:Wuesthoff Health System and Broadlane Continue Exclusive Relationship; Orthopedic Consulting Initiative Yields Significant Savings 4Health News:EMK Placental Appoints Beauty Beverly Hills for Exclusive Distributorship. 2Health News:EMK Placental Appoints Beauty Beverly Hills for Exclusive Distributorship. 3
... innovative capillary electrophoresis system is designed ... testing. The CAPILLARYS 2 utilizes liquid ... clinical diagnostic setting. Through continuous sample ... very narrow capillary tubes functioning concurrently, ...
... These unique Acid Fast Control ... smear with appropriate background material. ... a positive and negative smear. ... (Cat. No. 353), Ziehl-Neelsen or ...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Each slide contains Giardia lamblia trophozoites applied as a mono-layer to the side....
Medicine Products: